Advertisement

CAPTAIN: EFFECTS OF AGE OF ASTHMA ONSET AS A CONTINUOUS VARIABLE ON TREATMENT OUTCOMES

      TOPIC: Respiratory Care
      TYPE: Original Investigations
      PURPOSE: The CAPTAIN study showed that adding umeclidinium (UMEC) to fluticasone furoate/vilanterol (FF/VI) led to improvements in lung function and symptom control in patients with uncontrolled asthma on inhaled corticosteroid/long-acting β2-agonist (ICS/LABA). In a previous analysis of CAPTAIN, we showed that response to FF/UMEC/VI may vary according to the age at which a patient develops asthma (<18 vs ≥18 years of age). Here, we further explore potential differential treatment responses using age of asthma onset as a continuous variable.
      METHODS: This Phase IIIA, double-blind, 24–52-week, parallel-group study randomized adults with uncontrolled asthma despite ICS/LABA therapy (N=2436). Treatment: once-daily FF/VI (100/25, 200/25mcg) or FF/UMEC/VI (100/31.25/25, 100/62.5/25, 200/31.25/25, 200/62.5/25mcg) (ELLIPTA inhaler). Here we report post hoc analyses of change from baseline in clinic trough forced expiratory volume in 1 second (FEV1) at Week 24 (analyzed using mixed model repeated measures) and annualized rate of moderate/severe asthma exacerbations (Weeks 1–52; analyzed using a negative binomial model) according to age of asthma onset. Treatment groups were pooled by addition of UMEC 62.5mcg or FF dose. Fractional polynomial modelling was used to model the effect of age of asthma onset on each endpoint.
      RESULTS: Mean (SD) age of asthma onset and disease duration were 32.0 (18.74) and 21.2 (15.31) years, respectively. Greater improvements in trough FEV1 (~100mL) were seen following the addition of UMEC 62.5mcg to FF/VI across the range of ages at which asthma developed. Addition of UMEC appeared to be more effective at reducing the moderate/severe exacerbation rate with advancing age of asthma onset, however there was considerable overlap in the 95% confidence intervals. The higher FF dose (200mcg) was associated with small numerical improvements in trough FEV1 versus FF 100mcg irrespective of age of asthma onset, although there was some overlap in 95% confidence intervals. Furthermore, the improvements in trough FEV1 with the higher dose of FF were less pronounced compared with the effect of adding UMEC. The higher FF dose was also associated with numerically greater reductions in moderate/severe exacerbation rate versus FF 100mcg across the range of age of asthma onset. In all analyses there was greater uncertainty at the extremes due to lower numbers of patients.
      CONCLUSIONS: Addition of UMEC or use of the higher FF dose were generally associated with numerical improvements in treatment outcomes independent of age of asthma onset, except for the effect of adding UMEC on moderate/severe exacerbations among patients with the youngest age of onset where there was more uncertainty in the data.
      CLINICAL IMPLICATIONS: Improvements observed with the addition of UMEC 62.5mcg to FF/VI or use of the higher FF dose were generally independent of age of asthma onset.Funding: GSK (205715/NCT02924688).
      DISCLOSURES: Employee relationship with GSK Please note: Aug 2017 - current Added 04/20/2021 by Zelie Bailes, source=Web Response, value=Salary
      Employee relationship with GSK Please note: Aug 2017 - current Added 04/20/2021 by Zelie Bailes, source=Web Response, value=Ownership interest
      Employee relationship with GSK Please note: >$100000 by Neil Barnes, source=Web Response, value=Shares
      Participation in multicenter clinical research trials relationship with AstraZeneca Please note: $20001 - $100000 by Louis-Philippe Boulet, source=Admin input, value=Grant/Research Support
      Advisory Committee Member relationship with AstraZeneca Please note: $5001 - $20000 by Louis-Philippe Boulet, source=Admin input, value=Consulting fee
      Advisory Committee Member relationship with GSK Please note: $5001 - $20000 by Louis-Philippe Boulet, source=Admin input, value=Consulting fee
      Advisory Committee Member relationship with Merck Please note: $5001 - $20000 by Louis-Philippe Boulet, source=Admin input, value=Consulting fee
      Advisory Committee Member relationship with Novartis Please note: $5001 - $20000 by Louis-Philippe Boulet, source=Admin input, value=Consulting fee
      Advisory Committee Member relationship with Takeda Please note: $5001 - $20000 by Louis-Philippe Boulet, source=Admin input, value=Consulting fee
      Fees for consulting relationship with AstraZeneca Please note: $5001 - $20000 by Louis-Philippe Boulet, source=Admin input, value=Consulting fee
      Fees for consulting relationship with Merck Please note: $5001 - $20000 by Louis-Philippe Boulet, source=Admin input, value=Consulting fee
      Fees for consulting relationship with GSK Please note: $5001 - $20000 by Louis-Philippe Boulet, source=Admin input, value=Consulting fee
      Fees for consulting relationship with Metapharm Please note: $5001 - $20000 by Louis-Philippe Boulet, source=Admin input, value=Consulting fee
      Fees for consulting relationship with Novartis Please note: $5001 - $20000 by Louis-Philippe Boulet, source=Admin input, value=Consulting fee
      Fees for consulting relationship with Takeda Please note: $5001 - $20000 by Louis-Philippe Boulet, source=Admin input, value=Consulting fee
      Participation in multicenter clinical re relationship with Boston Scientific Please note: $20001 - $100000 by Louis-Philippe Boulet, source=Admin input, value=Grant/Research Support
      Participation in multicenter clinical re relationship with GSK Please note: $20001 - $100000 by Louis-Philippe Boulet, source=Admin input, value=Grant/Research Support
      Participation in multicenter clinical re relationship with Hoffman La Roche Please note: $20001 - $100000 by Louis-Philippe Boulet, source=Admin input, value=Grant/Research Support
      Participation in multicenter clinical re relationship with Ono Pharma Please note: $20001 - $100000 by Louis-Philippe Boulet, source=Admin input, value=Grant/Research Support
      Participation in multicenter clinical re relationship with Novartis Please note: $20001 - $100000 by Louis-Philippe Boulet, source=Admin input, value=Grant/Research Support
      Participation in multicenter clinical re relationship with Sanofi Please note: $20001 - $100000 by Louis-Philippe Boulet, source=Admin input, value=Grant/Research Support
      Participation in multicenter clinical re relationship with Takeda Please note: $5001 - $20000 by Louis-Philippe Boulet, source=Admin input, value=Grant/Research Support
      Participation in multicenter clinical re relationship with Boehringer Ingelheim Please note: $20001 - $100000 by Louis-Philippe Boulet, source=Admin input, value=Grant/Research Support
      Participation in multicenter clinical re relationship with Merck Please note: $20001 - $100000 by Louis-Philippe Boulet, source=Admin input, value=Grant/Research Support
      Production of educational material relationship with AstraZeneca Please note: $5001 - $20000 by Louis-Philippe Boulet, source=Admin input, value=Non profit grants
      Production of educational material relationship with Boehringer-Ingelheim Please note: $5001 - $20000 by Louis-Philippe Boulet, source=Admin input, value=Non profit grants
      Production of educational material relationship with GSK Please note: $20001 - $100000 by Louis-Philippe Boulet, source=Admin input, value=Non profit grants
      Production of educational material relationship with Merck Please note: $5001 - $20000 by Louis-Philippe Boulet, source=Admin input, value=Non profit grants
      Production of educational material relationship with Novartis Please note: $5001 - $20000 by Louis-Philippe Boulet, source=Admin input, value=Non profit grants
      Non profit grants relationship with Covis Please note: $5001 - $20000 by Louis-Philippe Boulet, source=Admin input, value=Grant/Research Support
      Employee relationship with GSK Please note: 2014-2021 Added 05/04/2021 by Frances Gardiner, source=Web Response, value=Salary
      Advisory Committee Member relationship with AstraZeneca, Genentech, GSK, Mylan, Sanofi Please note: 2020-2021 Added 04/20/2021 by Nicola Hanania, source=Web Response, value=Consulting fee
      Consultant relationship with AstraZeneca, Genentech, GSK, Mylan, Sanofi Please note: 2020-2021 Added 04/20/2021 by Nicola Hanania, source=Web Response, value=Consulting fee
      Advisory Committee Member relationship with Regeneron, Amgen, and Teva Please note: 2020-2021 Added 04/20/2021 by Nicola Hanania, source=Web Response, value=Consulting fee
      Consultant relationship with Regeneron, Amgen, and Teva Please note: 2020-2021 Added 04/20/2021 by Nicola Hanania, source=Web Response, value=Consulting fee
      Research support relationship with Boehringer Ingelheim, GSK, Novartis Please note: 2020-2021 Added 04/20/2021 by Nicola Hanania, source=Web Response, value=Grant/Research Support
      Research support relationship with Sanofi Genzyme and Genentech Please note: 2020-2021 Added 04/20/2021 by Nicola Hanania, source=Web Response, value=Grant/Research Supportresearch grant relationship with Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Sano Please note: one year Added 04/26/2021 by Hiromasa Inoue, source=Web Response, value=Grant/Research Support
      Speaker/Speaker's Bureau relationship with AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Kyorin, Please note: the moment Added 04/26/2021 by Hiromasa Inoue, source=Web Response, value=Honoraria
      Employee relationship with GSK Please note: >$100000 by Paul Jones, source=Web Response, value=Salary
      Advisory Committee Member relationship with GlaxoSmithKLine Please note: $1001 - $5000 by Huib Kerstjens, source=Web Response, value=Consulting fee
      Advisory Committee Member relationship with Novartis Please note: $1001 - $5000 by Huib Kerstjens, source=Web Response, value=Consulting fee
      Advisory Committee Member relationship with Boehringer Please note: $1001 - $5000 by Huib Kerstjens, source=Web Response, value=Consulting fee
      Consultant relationship with Amphastar Please note: 2012-present Added 04/20/2021 by Edward Kerwin, source=Web Response, value=Consulting fee
      Consultant relationship with AstraZeneca Please note: 2012-present Added 04/20/2021 by Edward Kerwin, source=Web Response, value=Consulting fee
      Speaker/Speaker's Bureau relationship with Boehringer Ingelheim Please note: 2015 Added 04/20/2021 by Edward Kerwin, source=Web Response, value=Honoraria
      Consultant relationship with Cipla Please note: 2016 Added 04/20/2021 by Edward Kerwin, source=Web Response, value=Consulting fee
      Speaker/Speaker's Bureau relationship with Chiesi Please note: 2018-present Added 04/20/2021 by Edward Kerwin, source=Web Response, value=Travel
      Consultant relationship with GlaxoSmithKline Please note: 2014-present Added 04/20/2021 by Edward Kerwin, source=Web Response, value=Consulting fee
      Advisory Committee Member relationship with Mylan Please note: 2012-present Added 04/20/2021 by Edward Kerwin, source=Web Response, value=Consulting fee
      Advisory Committee Member relationship with Novartis Please note: 2014-present Added 04/20/2021 by Edward Kerwin, source=Web Response, value=Consulting fee
      Speaker/Speaker's Bureau relationship with Sunovion Please note: 2012-present Added 04/20/2021 by Edward Kerwin, source=Web Response, value=Honoraria
      Advisory Committee Member relationship with Theravance Please note: 2015-2019 Added 04/20/2021 by Edward Kerwin, source=Web Response, value=Consulting fee
      Advisory Committee Member relationship with Connect Biopharma Please note: 2020-present Added 04/20/2021 by Edward Kerwin, source=Web Response, value=Consulting fee
      Advisory Committee Member relationship with AstraZeneca, Genentech, GSK, Novartis, Regeneron, Sanofi, and Teva Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Consulting fee
      Consultant relationship with AstraZeneca Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Consulting fee
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Advisory Committee Member relationship with GSK Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Consulting fee
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Advisory Committee Member relationship with Sanofi Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Consulting fee
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Advisory Committee Member relationship with Genentech Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Consulting fee
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Advisory Committee Member relationship with Novartis Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Consulting fee
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Advisory Committee Member relationship with TEVA Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Consulting fee
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Funds for devleoping CME presentations relationship with AKH Please note: >24 months Added 04/19/2021 by Njira Lugogo, source=Web Response, value=Grant/Research Support
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Advisory Committee Member relationship with AstraZeneca Please note: >24 months Added 04/19/2021 by Njira Lugogo, source=Web Response, value=Grant/Research Support
      Removed 04/19/2021 by Njira Lugogo, source=Web Response
      Clinical trials institution funding relationship with AstraZeneca Please note: >24 months Added 04/19/2021 by Njira Lugogo, source=Web Response, value=Grant/Research Support
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Funds for developing CME presentations relationship with Greentech Please note: >24 months Added 04/19/2021 by Njira Lugogo, source=Web Response, value=Grant/Research Support
      Removed 04/19/2021 by Njira Lugogo, source=Web Response
      Clinical trials institution funding relationship with Greentech Please note: >24 months Added 04/19/2021 by Njira Lugogo, source=Web Response, value=Grant/Research Support
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Clinical trials institution funding relationship with GSK Please note: >24 months Added 04/19/2021 by Njira Lugogo, source=Web Response, value=Grant/Research Support
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Clinical trials institution funding relationship with Novartis Please note: >24 months Added 04/19/2021 by Njira Lugogo, source=Web Response, value=Grant/Research Support
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Clinical trials institution funding relationship with Regeneron Please note: >24 months Added 04/19/2021 by Njira Lugogo, source=Web Response, value=Grant/Research Support
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Clinical trials institution funding relationship with Sanofi Please note: >24 months Added 04/19/2021 by Njira Lugogo, source=Web Response, value=Grant/Research Support
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Clinical trials institution funding relationship with Teva Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Grant/Research Support
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Advisory Committee Member relationship with GSK Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Consulting fee
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Advisory Committee Member relationship with Genentech Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Consulting fee
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Advisory Committee Member relationship with Novartis Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Consulting fee
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Advisory Committee Member relationship with Regeneron Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Consulting fee
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Advisory Committee Member relationship with Sanofi Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Consulting fee
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Advisory Committee Member relationship with Teva Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Consulting fee
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Clinical trial funding for institution relationship with AstraZeneca, Genentech, GSK, Regeneron, Sanofi and Teva Please note: >24 months Added 04/26/2021 by Njira Lugogo, source=Web Response, value=Grant/Research Support
      Clinical trial funding for institution relationship with Genentech Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Grant/Research Support
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Clinical trial funding for institution relationship with GSK Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Grant/Research Support
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Clinical trial funding for institution relationship with Novartis Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Grant/Research Support
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Clinical trial funding for institution relationship with Regeneron Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Grant/Research Support
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Clinical trial funding for institution relationship with Sanofi Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Grant/Research Support
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Clinical trial funding for institution relationship with Teva Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Grant/Research Support
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      Consultant relationship with AstraZeneca Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Consulting fee
      Funds for developing CME presentations relationship with AKH, Medscape and NACE Please note: >24 months Added 04/26/2021 by Njira Lugogo, source=Web Response, value=Grant/Research Support
      Funds for devleoping CME presentations relationship with Medscape Please note: >24 months Added 04/20/2021 by Njira Lugogo, source=Web Response, value=Grant/Research Support
      Removed 04/20/2021 by Njira Lugogo, source=Web Response
      No relevant relationships by Robert Nathan, source=Web Response
      Advisory Committee Member relationship with AstraZeneca Please note: 24 months Added 04/21/2021 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Consultant relationship with AstraZeneca Please note: 24 months Added 04/21/2021 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Speaker/Speaker's Bureau relationship with AstraZeneca Please note: 24 months Added 04/21/2021 by Reynold Panettieri, source=Web Response, value=Honoraria
      Advisory Committee Member relationship with RIFM Please note: 24 months Added 04/21/2021 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Consultant relationship with RIFM Please note: 24 months Added 04/21/2021 by Reynold Panettieri, source=Web Response, value=Honoraria
      Consultant relationship with Equillium Please note: 24 months Added 04/21/2021 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Advisory Committee Member relationship with Equillium Please note: 24 months Added 04/21/2021 by Reynold Panettieri, source=Web Response, value=Honoraria
      Advisory Committee Member relationship with Genetech Please note: 24 months Added 04/21/2021 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Speaker/Speaker's Bureau relationship with Genetech Please note: 24 months Added 04/21/2021 by Reynold Panettieri, source=Web Response, value=Honoraria
      Speaker/Speaker's Bureau relationship with Sanofi/Regeneron Please note: 24 months Added 04/21/2021 by Reynold Panettieri, source=Web Response, value=Honoraria
      Consultant relationship with Bayer Please note: 24 months Added 04/21/2021 by Reynold Panettieri, source=Web Response, value=Honoraria
      Advisory Committee Member relationship with Theravance Please note: 24 months Added 04/21/2021 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Contracted Research relationship with Novartis Please note: 24 months Added 04/21/2021 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Contracted Research relationship with Optikira Please note: 24 months Added 04/21/2021 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Contracted Research relationship with Medimmune Please note: 24 months Added 04/21/2021 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Contracted Research relationship with Maven Please note: 24 months Added 04/21/2021 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Contracted Research relationship with Evelobio Please note: 24 months Added 04/21/2021 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Contracted Research relationship with Johnson & Johnson Please note: 24 months Added 04/21/2021 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Advisory Committee Member relationship with AstraZeneca; RIFM; Equillium; Genentech; Thervance Please note: 24 months Added 04/22/2021 by Reynold Panettieri, source=Web Response, value=Honoraria
      Consultant relationship with AstraZeneca; RIFM; Equillium; Bayer Please note: 24 months Added 04/22/2021 by Reynold Panettieri, source=Web Response, value=Honoraria
      Speaker/Speaker's Bureau relationship with AstraZeneca; Sanofi/Regeneron; Genentech Please note: 24 months Added 04/22/2021 by Reynold Panettieri, source=Web Response, value=Honoraria
      Research grant recipient relationship with Novartis; Optikira; Medimmune; Maven; Evelobio Please note: 24 months Added 04/22/2021 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Research grant recipient relationship with Johnson & Johnson; AstraZeneca; RIFM; Equillium; Genentech Please note: 24 months Added 04/22/2021 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Research grant recipient relationship with Theravance Please note: 24 months Added 04/22/2021 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Advisory Committee Member relationship with AstraZeneca Please note: $1001 - $5000 by Reynold Panettieri, source=Web Response, value=Consulting fee
      Principal Investigator relationship with AstraZeneca Please note: $20001 - $100000 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Speaker/Speaker's Bureau relationship with AstraZeneca Please note: $1001 - $5000 by Reynold Panettieri, source=Web Response, value=Honoraria
      Advisory Committee Member relationship with MedImmune Please note: $1001 - $5000 by Reynold Panettieri, source=Web Response, value=Consulting fee
      Principal Investigator relationship with MedImmune Please note: $20001 - $100000 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Advisory Committee Member relationship with Reseaerch Institute for Fragrance Materials Please note: $1001 - $5000 by Reynold Panettieri, source=Web Response, value=Consulting fee
      Principal Investigator relationship with Reseaerch Institute for Fragrance Materials Please note: $20001 - $100000 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Advisory Committee Member relationship with Equillium Please note: $1001 - $5000 by Reynold Panettieri, source=Web Response, value=Consulting fee
      Principal Investigator relationship with Equillium Please note: $20001 - $100000 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Advisory Committee Member relationship with Theravance Please note: $1001 - $5000 by Reynold Panettieri, source=Web Response, value=Consulting fee
      Advisory Committee Member relationship with Avillion Please note: $1001 - $5000 by Reynold Panettieri, source=Web Response, value=Consulting fee
      Speaker/Speaker's Bureau relationship with Sanofi/Regeneron Please note: $1001 - $5000 by Reynold Panettieri, source=Web Response, value=Honoraria
      Speaker/Speaker's Bureau relationship with Genentech Please note: $1001 - $5000 by Reynold Panettieri, source=Web Response, value=Honoraria
      Principal Investigator relationship with Genentech Please note: $20001 - $100000 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Principal Investigator relationship with OncoArendi Please note: $20001 - $100000 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Principal Investigator relationship with Metera Please note: $20001 - $100000 by Reynold Panettieri, source=Web Response, value=Grant/Research Support
      Employee relationship with GSK Please note: January 2016 Added 04/27/2021 by Emilio Pizzichini, source=Web Response, value=Salary
      Employee relationship with GSK Please note: January 2016 Added 04/27/2021 by Emilio Pizzichini, source=Web Response, value=Salary
      Employee relationship with GSK Please note: >$100000 by David Slade, source=Web Response, value=Salary
      Former Employee relationship with Astra Zeneca Please note: >$100000 by David Slade, source=Web Response, value=Stock
      Employee relationship with GSK Please note: >$100000 by David Slade, source=Web Response, value=Stock
      Former Employee relationship with Teva Please note: >$100000 by David Slade, source=Web Response, value=Stock